SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes
ConclusionOur findings suggest SGLT2 inhibitors use was not associated with breast cancer risk compared with DPP4 inhibitors use. Studies with longer follow-up and better adjustments are needed to confirm the finding.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | SGLT2 Inhibitors | Study | Women